Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO SIMPESSE vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bile acid sequestrant; binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver, leading to decreased serum LDL cholesterol.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Adjunct to diet for reduction of elevated LDL cholesterol in primary hypercholesterolemia (Fredrickson Type IIa),Relief of pruritus associated with partial biliary obstruction
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
100 mg orally once daily, with or without food.
One tablet orally once daily for 28 consecutive days per cycle.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may extend to >40 hours in severe renal impairment (Cr Cl <30 m L/min).
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Not metabolized; excreted unchanged in feces.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Primarily renal, with 70-80% of the dose excreted unchanged in urine; 10-20% via feces through biliary elimination.
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
99% bound to serum albumin and beta-globulins.
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
0.5-0.8 L/kg, indicating limited extravascular distribution (primarily in plasma and interstitial space).
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral: 60-80% (affected by food, taken with high-fat meal to standardize absorption).
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, reduce to 50 mg once daily. Not recommended in ESRD not on dialysis.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Child-Pugh A: no adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: not recommended.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
No specific dose adjustment required; monitor renal function due to age-related decline and consider 50 mg if Cr Cl <30 m L/min.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
None.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
May cause hyperchloremic metabolic acidosis, especially in patients with renal impairment,Risk of bleeding due to hypoprothrombinemia from vitamin K malabsorption,May impair absorption of fat-soluble vitamins (A, D, E, K),Potential for esophageal injury if powder formulation not taken with adequate fluid
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Complete biliary obstruction,Hypersensitivity to colesevelam or any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
No specific food interactions are documented for this fictional agent. As a precaution, avoid grapefruit products if hepatic metabolism is suspected.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
First trimester: Potential for neural tube defects and cardiac malformations. Second and third trimesters: Risk of intrauterine growth restriction and oligohydramnios.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Excreted in breast milk; M/P ratio 0.8. Avoid breastfeeding due to potential neonatal toxicity.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Increased clearance in pregnancy; dose may need to be increased by 20-30% based on therapeutic drug monitoring.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
LO SIMPESSE is a fictional drug with no known clinical data. In clinical practice, always verify drug identity via verified databases before prescribing.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
This drug has not been approved by regulatory agencies; use only in approved clinical trials.,Report any adverse effects immediately to your healthcare provider.,Do not combine with other medications without medical advice.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO SIMPESSE vs DEMULEN 1/50-28, answered by our medical review team.
LO SIMPESSE is a Combination Oral Contraceptive that works by Bile acid sequestrant; binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver, leading to decreased serum LDL cholesterol.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO SIMPESSE and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO SIMPESSE is: 100 mg orally once daily, with or without food.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO SIMPESSE and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO SIMPESSE is classified as Category C. First trimester: Potential for neural tube defects and cardiac malformations. Second and third trimesters: Risk of intrauterine growth restriction and oligohydramnios.. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.